Roche Failure Leaves Industry Reassessing Alzheimer's Space

The beta-amyloid theory in Alzheimer’s disease took another hit Monday when Roche announced that gantenerumab failed to meet the primary endpoint in two Phase III studies.

The biopharma industry has spent the past two days responding in various ways. Several of Roche’s competitors, including Biogen, Cassava Sciences and Eli Lilly saw their stocks rise as a result.